NCT01453205 2018-03-12
A Phase 2, Multicenter, Randomized, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
MedImmune LLC
Phase 2 Completed
MedImmune LLC
Barbara Ann Karmanos Cancer Institute
GlaxoSmithKline